Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
NCT02471183
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG:
Selexipag
Sponsor
Actelion